Close Menu

NEW YORK – Meridian Bioscience announced Wednesday it has entered into a definitive agreement to acquire gastrointestinal diagnostic firm Exalenz Bioscience for 6.10 Israeli shekels per share, implying a transaction value of 169 million Israeli shekels, or $49 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.